YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The YONDELIS (trabectedin) Single Patient Compassionate Use /Expanded Access program provides
patients with advanced soft tissue sarcoma, who do not qualify for ongoing clinical trials
with YONDELIS (trabectedin), access to this investigational treatment.
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.